Nevertheless, the combination of trastuzumab and both PPRHs against ERBB2 revealed a certain degree of synergism depending on the concentration of PPRH tested, confirming the potential applicability of such combinations as therapeutic strategies for HER-2-positive breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.